Articles by author - Matus Kolarik

Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.

Kolarik M, Indra R, Adam V, Heger Z, Kopeckova K, Arlt V, Stiborova M.

Journal Article 2019; 39(7): 515-524 PubMed PMID: 30860683  Keywords:  Anilides:pharmacology, Animals, Cytochrome P-450 Enzyme Inhibitors:pharmacology, Ellipticines:pharmacokinetics, Humans, Microsomes, Liver:drug effects, Oxidation-Reduction:drug effects, Peroxidases:antagonists & inhibitors, Phenylurea Compounds:pharmacolo.    Citation

OBJECTIVES: Vandetanib¸ lenvatinib, and cabozantinib are tyrosine kinase inhibitors (TKIs) targeting VEGFR subtypes 1 and 2, EGFR and the.....

Read abstract  Full text PDF